Company profile for GV20 Therapeutics

PharmaCompass

Only Regulatory Products (API/FDF), Drugs in Developments and News are Updated on this Virtual Booth

Update your Virtual Booth on PharmaCompass, ask us

About

GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfoli...
GV20 Therapeutics, established in 2016 with locations in Cambridge, USA, and Shanghai, China, is at the forefront of cancer immunology research. Leveraging high-throughput functional genomics and artificial intelligence (AI) methodologies, the company identifies novel drug targets in cancer immunology and develops effective antibody drugs. Through its proprietary antibody drug discovery engine, GV20 has built a robust portfolio of immuno-oncology antibody drug candidates for cancer treatment.

List your booth number for exhibitions, ask us

CONTACT DETAILS

Click the arrow to open the dropdown
Country
Country
U.S.A
Address
Address
Cambridge, MA 02139
Telephone
Telephone
youtube
YouTube
Twitter
Twitter

Upload your Marketing & Sales content on your company Virtual Booth, click HERE.

Events

Webinars & Exhibitions

Default Event

DDL Conference

Not Confirmed

envelop Contact Supplier

DDL Conference

Post an Enquiry

Meeting

Digital content

Create Content with PharmaCompass, ask us

NEWS #PharmaBuzz

read-more
read-more

https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-achievement-of-milestone-under-antibody-drug-conjugate-collaboration-with-mitsubishi-tanabe-pharma-corporation-302625157.html

PR NEWSWIRE
25 Nov 2025

https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-updated-phase-1-monotherapy-data-on-gv20-0251-at-the-asco-annual-meeting-2025-302463357.html

PR NEWSWIRE
23 May 2025

https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-collaboration-agreement-with-mitsubishi-tanabe-pharma-corporation-to-develop-novel-antibody-drug-conjugates-302411169.html

PR NEWSWIRE
27 Mar 2025

https://www.prnewswire.com/news-releases/gv20-therapeutics-presents-promising-phase-1-monotherapy-data-on-novel-checkpoint-inhibitor-gv20-0251-at-esmo-congress-2024-302247149.html

PR NEWSWIRE
16 Sep 2024

https://www.prnewswire.com/news-releases/gv20-therapeutics-to-present-clinical-data-on-gv20-0251-at-the-esmo-congress-2024-302225841.html

PR NEWSWIRE
21 Aug 2024

https://www.prnewswire.com/news-releases/gv20-therapeutics-announces-publication-in-cell-highlighting-the-discovery-of-igsf8-as-an-innate-immune-checkpoint-and-cancer-immunotherapy-target-302126064.html

PR NEWSWIRE
24 Apr 2024

ABOUT THIS PAGE

Ask Us for Pharmaceutical Supplier and Partner
Ask Us, Find A Supplier / Partner
No Commissions, No Strings Attached, Get Connected for FREE

What are you looking for?

How can we help you?

The request can't be empty

Please read our Privacy Policy carefully

You must agree to the privacy policy

The name can't be empty
The company can't be empty.
The email can't be empty Please enter a valid email.
The mobile can't be empty